Provectus Biopharmaceuticals Announces Acceptance of PV-10® Neuroendocrine Cancer Abstract for Oral Presentation at 2022 European Neuroendocrine Tumor Society (ENETS) Annual Conference KNOXVILLE, TN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium),...

Provectus Biopharmaceuticals Announces Presentation of Full Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at European Society for Medical Oncology (ESMO) Congress 2021 KNOXVILLE, TN, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal...

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Neuroendocrine Cancer Abstract at European Society for Medical Oncology (ESMO) Congress 2021 KNOXVILLE, TN, July 19, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal disodium)...